Hepatoma 1
Hepatoma 1
Hepatoma 1
Epidemiologi
Klasifikasi
Etiologi & Faktor Risiko
Manifestasi Klinis
Diagnosis
Sistem staging
Terapi
Parkin, D.M., et al., Global cancer statistics, 2002. CA Cancer J Clin, 2005. 55(2): p. 74-108.
#6
Estimated Numbers
of New Cancer
Cases and Deaths in
2002
6% 5 yr survival rate
#7
El-Serag, H.B. and A.C. Mason, Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med, 1999. 340(10): p. 745-50.
JINAK
GANAS
Tumor Epitelial
Adenoma hepatoselular
Adenoma bilier intrahepatik
Sistadenoma bilier intrahepatik
Papilomatosis bilier
Karsinoma hepatoselular
Karsinoma fibrolamelar
Hepatoblastoma
Kolangiokarsinoma
Sistadenokarsinoma
Tumor Mesenkimal
Hemangioma
Fibroma
Leiomioma
Lipoma
Angiomiolipoma
Limfangioma
Mesotelioma
Angiosarkoma
Fibrosarkoma
Leiomiosarkoma
Liposarkoma
Rabdomiosarkoma
Limfoma hepatik primer
Hemangioendoteliomaepitelioid
Virus hepatitis B
Virus hepatitis C
Faktor-faktor risiko:
Sirosis hati, pada 60-80% SH makronodular dan 3-10% SH
mikronodular
Aflatoksin
Obesitas
Diabetes melitus hiperinsulinemia dan peningkatan insulinlike growth factors.
Alkohol
Penyakit hati autoimun
Penyakit hati metabolik (hemokromatosis, defisiensi alfa-1antitripsin, penyakit Wilson)
Kontrasepsi oral
Senyawa kimia (vinyl chloride, thorotrast, nitrosamin,
insektisida organoklorin, asam tanik)
Tembakau (masih kontroversi)
HBV
5-15 fold increased risk
70-90% of cases occur in setting
of cirrhosis
Treatment does NOT decrease risk
Risk highest in carriers and lower
in immune
HCV
1-3% of cirrhotic patients develop
HCC
Treatment seems to decrease risk
Co-infection
Aflatoxins (Aspergillus fumigatus)
4 fold increased risk HCC
Alcohol
>50-70g/day
No link to direct carcinogenic
effect
Synergistic with HCV and HBV
Nonalcoholic Steatohepatitis?
El-Serag, H.B. and K.L. Rudolph, Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 2007. 132(7): p. 2557-76.
Brunetto M.R., O.F., Koehler M., et al., Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study.
International Interferon-alpha Hepatocellular Carcinoma Study Group. Lancet, 1998. 351(9115): p. 1535-9.
Obesity
Diabetes Mellitus
Hemochromatosis
Alpha-1 antitrypsin deficiency
Autoimmune hepatitis
Porphyrias
15-50% of HCC in the US have no
established risk factors
Score
Tumor Morphology
AFP
Score
Average survival
31 Mon.
Uninodular , <50%
27 Mon.
Multinodular, <50%
13 Mon.
Massive, >50%
8 Mon.
<400
> 4
2 Mon.
>400
yes
1
Bilirubin
Albumin
INR
Ascites
Encephalop
athy
<2
>3.5
2-3
3.5-2.8
>3
<2.8
<1.7
Absen
t
Absen
t
1.7-2.3
MildModerate
Mild (I-II)
>2.3
Severe /
Refractory
Severe (III-IV)
Stage I
T1
N0
M0
Stage II
T2
N0
M0
N0
M0
N0
N1
M0
M0
Stage
T3
IIIA
IIIB T4
IIIC Any T
T definitions
55% 5 yr
survival
37% 5 yr
survival
16% 5 yr
survival
Stage
T1 solitary
nodule
IV Any
T without
Any Nvascular
M1 invasion
T2 solitary tumor with vascular invasion or multiple
Criteria
Tumor size
Positive
>50%
Negative
<50%
Ascites
Clinically
detectable
<3
Abscent
Albumin
Bilirubin
Stage I
>3
No positive
>3
<3
8.3 mos
survival
Stage II
1-2 positive
2 mos survival
Stage III
3-4 positive
0.7 mos
survival
Adapted from Okuda, K, Ohtuiki, T, Obata, H,
et al, Cancer 1985; 56:918
Primary prevention
Taiwan: HBV immunization of newborns
Chang, M.H., et al., Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children.
Taiwan Childhood Hepatoma Study Group. N Engl J Med, 1997. 336(26): p. 1855-9.
Transarterial chemoembolization
(TACE)
2 yr survival 24-63%
No vascular invasion, preserved liver
Radiation therapy
Systemic chemotherapy
>100 trials over the last 30 years
Transarterial chemoembolization
(TACE)
2 yr survival 24-63%
No vascular invasion, preserved liver
Radiation therapy
Systemic chemotherapy
>100 trials over the last 30 years
Reseksi hepatik: untuk pasien dalam kelompok nonsirosis (klasifikasi Child Pugh A) dan fungsi hati normal.
Reseksi juga pada kelompok HCC lokalisata (kelainan
pada satu lobus hati/(Selected T1 and T2; N0; M0) ),
bagian hati yang direseksi termasuk bagian normal hati
1cm.
Transplantasi hati: untuk pasien HCC dan sirosis hati.
Pada pasien HCC lokalisata yang parah/advance
(Selected T1, T2, T3, and T4; N0; M0), bila tidak
dilakukan reseksi Ablasi tumor perkutan: Injeksi etanol
perkutan; Radiofrequency ablation; Polyprenoic acid.
Terapi paliatif: Transarterial embolization/chemo
embolization khususnya pada HCC difus dua lobus atau
belum ada metastase ekstrahepatik. Bila ada metastase
ekstrahepatik, angka mortalitasnya tinggi. (Any T, N1 or
M1)